Literature DB >> 17805327

Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.

C Haferlach1, F Dicker, S Schnittger, W Kern, T Haferlach.   

Abstract

In CLL data from chromosome banding analysis (CBA) have been scarce due to the low proliferative activity of CLL cells in vitro. We improved the cultivation technique using an immunostimulatory CpG-oligonucleotide DSP30 and IL-2. A total of 506 CLL samples were analysed with CBA and interphase FISH using probes for the detection of trisomy 12, IgH rearrangements and deletions of 6q21, 11q22.3 (ATM), 13q14 (D13S25 and D13S319) and 17p13 (TP53). A total of 500 of 506 (98.8%) cases were successfully stimulated for metaphase generation and are subject to this study. Aberrations were detected in 415 of 500 (83.0%) cases by CBA and in 392 of 500 (78.4%) cases by FISH. CBA detected 832 abnormalities and FISH only 502. Therefore, CBA offers important information in addition to FISH. (1) CLL is characterized mainly by genomic imbalances and reciprocal translocations are rare. (2) A subgroup with complex aberrant karyotype (16.4%) is identified which is associated with an unmutated IgV(H) status and CD38 expression (P=0.034 and 0.02, respectively). (3) Additional abnormalities are detectable providing new biological insights into different CLL subclasses revealing a much more heterogeneous pattern of cytogenetic abnormalities as assumed so far based on FISH data only. Therefore, prospective clinical trials should evaluate the prognostic impact of newly available CBA data.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17805327     DOI: 10.1038/sj.leu.2404935

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  95 in total

1.  miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Angelo Veronese; Laura Z Rassenti; Veronica Balatti; Dennis K Pearl; Mario Acunzo; Stefano Volinia; Cristian Taccioli; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

2.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

3.  Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.

Authors:  Natarajan Muthusamy; Heather Breidenbach; Leslie Andritsos; Joseph Flynn; Jeffrey Jones; Asha Ramanunni; Xiaokui Mo; David Jarjoura; John C Byrd; Nyla A Heerema
Journal:  Cancer Genet       Date:  2011-02

4.  Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia.

Authors:  Rachel Sargent; Dan Jones; Lynne V Abruzzo; Hui Yao; Jaime Bonderover; Marissa Cisneros; William G Wierda; Michael J Keating; Rajyalakshmi Luthra
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

5.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

6.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

7.  The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study.

Authors:  Shuhua Yi; Heng Li; Zengjun Li; Wenjie Xiong; Huimin Liu; Wei Liu; Rui Lv; Zhen Yu; Dehui Zou; Yan Xu; Gang An; Lugui Qiu
Journal:  Int J Hematol       Date:  2017-04-24       Impact factor: 2.490

8.  BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.

Authors:  Victor S Lin; Thomas E Lew; Sasanka M Handunnetti; Piers Blombery; Tamia Nguyen; David A Westerman; Bryone J Kuss; Constantine S Tam; Andrew W Roberts; John F Seymour; Mary Ann Anderson
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

Review 9.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

10.  Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.

Authors:  Peter Ouillette; Samuel Fossum; Brian Parkin; Li Ding; Paula Bockenstedt; Ammar Al-Zoubi; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.